Pharmaceuticals, Biotechnology and Life Sciences
Primary efficacy analysis demonstrated promising efficacy for capmatinib irrespective of the prior line of therapy in 97 patients: overall response…
Presentation of SENS-111 phase 2 study protocol in Acute Unilateral Vestibulopathy (AUV) MONTPELLIER, France–(BUSINESS WIRE)–Regulatory News: Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN)…
– The Phase III POLYP 1 and POLYP 2 studies of Xolair in adults with chronic rhinosinusitis with nasal polyps…
CUPERTINO, Calif.–(BUSINESS WIRE)–Reviva Pharmaceuticals, Inc. (Reviva), a privately held, clinical stage pharmaceutical company today announced that it has successfully completed…
Addition to management team strengthens Lyndra’s development capabilities WATERTOWN, Mass.–(BUSINESS WIRE)–#CEO–Lyndra Therapeutics, the company making daily pills a thing of…
GENEVA & OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (“Takeda”) (TSE:4502/NYSE:TAK) today became the first private sector company to announce a…
• Pivotal Phase 3 data presented in ASCO oral session and simultaneously published in The Lancet • The Phase 3…
Subcutaneous formulation also showed reduced administration time and lower rates of infusion-related reactions compared to intravenous administration BEERSE, Belgium–(BUSINESS WIRE)–The…
Investigational treatment demonstrates favorable early safety and efficacy data in patients who had received a median five prior treatments including…
Investigational treatment demonstrates favorable early safety and efficacy data in patients who had received a median five prior treatments including…